Rich Tyvin A, Shepard Robert
Department of Radiation Oncology, University of Virginia Health Sciences System, Charlottesville 22901, USA.
Am J Clin Oncol. 2003 Aug;26(4):S110-3. doi: 10.1097/01.COC.0000074148.37768.3E.
Cancers of the esophagus, stomach, and pancreas have been successfully treated recently with combinations of radiosensitizing chemotherapy and irradiation. New approaches building onto 5-fluorouracil chemoradiation include capecitabine (Xeloda) and irradiation. Capecitabine is an oral 5-fluorouracil (5-FU) prodrug that is more convenient than using infusional 5-FU, appears to have a similar therapeutic profile, and can be combined with daily irradiation. The addition of a cyclooxygenase-2 (COX-2) inhibitor is being investigated in upper gastrointestinal cancer sites because there is a high degree of overexpression of COX-2 in these cancers.
近期，采用放射增敏化疗与放疗相结合的方法已成功治疗了食管癌、胃癌和胰腺癌。在5-氟尿嘧啶化放疗基础上发展而来的新方法包括卡培他滨（希罗达）与放疗。卡培他滨是一种口服的5-氟尿嘧啶（5-FU）前体药物，比使用静脉输注的5-FU更方便，似乎具有相似的治疗效果，并且可与每日放疗联合使用。由于在上消化道癌部位环氧化酶-2（COX-2）高度过表达，因此正在对添加COX-2抑制剂进行研究。
